Artesunate Ointment for the Treatment of High Grade Vulvar Intraepithelial Neoplasia (HSIL VIN2/3)
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Women's Studies |
| Therapuetic Areas: | Reproductive |
| Healthy: | No |
| Age Range: | 18 - 100 |
| Updated: | 4/6/2019 |
| Start Date: | April 2019 |
| End Date: | July 1, 2021 |
| Contact: | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Email: | Jhcccro@jhmi.edu |
| Phone: | 410-955-8866 |
A Phase I Proof-of-Concept Study of Artesunate Ointment for the Treatment of Patients With High-Grade Vulvar Intraepithelial Neoplasia (HSIL VIN 2/3)
This is a Phase I, proof-of-concept treatment study to evaluate the safety, tolerability and
feasibility of topical artesunate ointment to treat high grade vulvar intraepithelial
neoplasia (HSIL VIN2/3).
feasibility of topical artesunate ointment to treat high grade vulvar intraepithelial
neoplasia (HSIL VIN2/3).
Phase I open-label dose escalation study of topical artesunate, formulated as ointment, in
the treatment of adult females with biopsy-confirmed HSIL VIN2/3. Fifteen (15) subjects will
undergo up to a total of three cycles of topical artesunate. The first cycle will be
initiated on Day 0, the second at Week 2, and the third and final cycle at week 4.
Primary Objective:
To evaluate the safety and tolerability of artesunate ointment applied topically on VIN2/3
lesions
To measure the effect of artesunate ointment on histologic regression of HSIL/VIN2/3 to VIN1
or less, confirmed by a colposcopically-directed biopsy, at study week 15.
the treatment of adult females with biopsy-confirmed HSIL VIN2/3. Fifteen (15) subjects will
undergo up to a total of three cycles of topical artesunate. The first cycle will be
initiated on Day 0, the second at Week 2, and the third and final cycle at week 4.
Primary Objective:
To evaluate the safety and tolerability of artesunate ointment applied topically on VIN2/3
lesions
To measure the effect of artesunate ointment on histologic regression of HSIL/VIN2/3 to VIN1
or less, confirmed by a colposcopically-directed biopsy, at study week 15.
Inclusion Criteria:
- Colposcopically-directed biopsy diagnosis of high-grade vulvar dysplasia (VIN2, VIN3,
VIN2/3, HSIL), including both new and recurrent disease.
- Females of childbearing potential: negative urine pregnancy test
- Ability to provide informed consent
- Ability to collaborate with planned follow-up (transportation, compliance history,
etc.)
- Use of contraception through the study exit visit (week 28)
Exclusion Criteria:
- History of anal, vulvar, cervical or oropharyngeal HPV cancers
- History of any other malignancy, except for non-melanoma skin lesions
- Cluster of differentiation 4 (CD4) count < 200 at the time of screening for
eligibility.
- Unable to provide informed consent
- Currently receiving systemic chemotherapy or radiation therapy for another cancer.
- Pregnant females
We found this trial at
1
site
Click here to add this to my saved trials
